Journal: Molecules

Article Title: Antibacterial Cotton Fabric Functionalized with Copper Oxide Nanoparticles

doi: 10.3390/molecules25245802

Figure Lengend Snippet: Summary of the functionalization of textile materials with CuO NPs conducted by the in situ method.

Article Snippet: 10 mM CuSO 4 , Cotton , NR , NR , Dip coating , The fabric was washed with nonionic agent Felosan RG-N and modified with 20 mL of the oxalic acid solutions of different concentrations (4, 6, and 10 w/v% ). , Antibacterial activity , NR , E. coli (ATCC 25922, NCTC 13846, ATCC BAA-2469), S. aureus (ATCC 25,923 and 43,300), P. aeruginosa (ATCC 27853), C. albicans (ATCC 24433), K. pneumoniae (ATCC BAA-2146) , ASTM E 2149-01 , [ ] .

Techniques: In Situ, Activity Assay, Irradiation, Modification, Diffusion-based Assay, Clinical Proteomics

Journal: Molecules

Article Title: Antibacterial Cotton Fabric Functionalized with Copper Oxide Nanoparticles

doi: 10.3390/molecules25245802

Figure Lengend Snippet: Summary of the functionalization of textile materials with CuO NPs by the ex situ method.

Article Snippet: 10 mM CuSO 4 , Cotton , NR , NR , Dip coating , The fabric was washed with nonionic agent Felosan RG-N and modified with 20 mL of the oxalic acid solutions of different concentrations (4, 6, and 10 w/v% ). , Antibacterial activity , NR , E. coli (ATCC 25922, NCTC 13846, ATCC BAA-2469), S. aureus (ATCC 25,923 and 43,300), P. aeruginosa (ATCC 27853), C. albicans (ATCC 24433), K. pneumoniae (ATCC BAA-2146) , ASTM E 2149-01 , [ ] .

Techniques: Ex Situ, Activity Assay, Synthesized, Irradiation, Diffusion-based Assay, Produced

Journal: International Journal of Nanomedicine

Article Title: Single-walled carbon nanotubes-ciprofloxacin nanoantibiotic: strategy to improve ciprofloxacin antibacterial activity

doi: 10.2147/IJN.S140625

Figure Lengend Snippet: Results of the zone of inhibition for f -SWCNTs 12 , ciprofloxacin, and p -SWCNTs

Article Snippet: The antibacterial activity of f -SWCNTs 12 was studied against Escherichia coli (ATCC 25922), Staphylococcus aureus (ATCC 25923), and Pseudomonas aeruginosa (ATCC 27853) strains and compared to the activity of ciprofloxacin and pristine SWCNT ( p -SWCNTs) alone.

Techniques: Inhibition

Journal: International Journal of Nanomedicine

Article Title: Single-walled carbon nanotubes-ciprofloxacin nanoantibiotic: strategy to improve ciprofloxacin antibacterial activity

doi: 10.2147/IJN.S140625

Figure Lengend Snippet: MIC of f -SWCNTs 12 compared to that of ciprofloxacin

Article Snippet: The antibacterial activity of f -SWCNTs 12 was studied against Escherichia coli (ATCC 25922), Staphylococcus aureus (ATCC 25923), and Pseudomonas aeruginosa (ATCC 27853) strains and compared to the activity of ciprofloxacin and pristine SWCNT ( p -SWCNTs) alone.

Techniques:

Journal: European Journal of Medicinal Chemistry

Article Title: Structure-activity relationships of potentiators of the antibiotic activity of clarithromycin against Escherichia coli

doi: 10.1016/j.ejmech.2019.05.075

Figure Lengend Snippet: Figure 3. Membrane permeabilization assays of 16 in E. coli ATCC 25922. Polymyxin B was included as a comparator membrane-targeting agent. Both 16 and polymyxin B were used at concentrations ranging from 1/32X to 1/2X the minimum inhibitory concentration (MIC), with the MIC values of 16 and polymyxin B being 100 and 1.56 µg/ml, respectively. The compound vehicle was DMSO. (A,B) Impact of E. coli treatment with 16 (A) or polymyxin B (B) on the intensity of the fluorophore N- phenyl-1-naphthylamine (NPN) at a concentration of 10 µM. (C,D) Impact of treatment with 16 (C) or polymyxin B (D) on the percentage of E. coli cells stained with the fluorophore propidium iodide (PI) at a concentration of 50 µM.

Article Snippet: M AN US CR IP T AC CE PT ED Graphical Abstract Compound 16 is associated with a 32-fold enhancement in the potency of clarithromycin against E. coli ATCC 25922 in vitro Graphical Abstract Compound 16 is associated with a 32-fold enhancement in the potency of clarithromycin against E. coli ATCC 25922 in vitro H2N H N NH2 16 H2N H N NH2 16 M AN US CR IP T AC CE PT ED -1- Structure-Activity Relationships of Potentiators of the Antibiotic Activity of Clarithromycin against Escherichia coli Gifty Blanksona, Ajit K. Parhia,c, Malvika Kaulb, Daniel S. Pilchb and Edmond J. LaVoiea aDepartment of Medicinal Chemistry, Rutgers, The State University of New Jersey, Piscataway, New Jersey, 08820, U.S.A. bDepartment of Pharmacology, Rutgers Robert Wood Johnson Medical School, Piscataway, New Jersey 08854, U.S.A cTAXIS Pharmaceuticals, Inc., Monmouth Junction, New Jersey 08552, U.S.A. 1.

Techniques: Membrane, Concentration Assay, Staining

Journal: European Journal of Medicinal Chemistry

Article Title: Structure-activity relationships of potentiators of the antibiotic activity of clarithromycin against Escherichia coli

doi: 10.1016/j.ejmech.2019.05.075

Figure Lengend Snippet: Figure 4. Assay for inhibition of the efflux of the fluorophore Hoechst 33342 (H33342) by 16 in E. coli ATCC 25922. When present, 16 was used at concentrations ranging from 1/32X to 1/2X MIC (3.13 to 50 µg/mL). All reactions were initiated by the addition of 50 mM glucose except where indicated. H33342 was used at a concentration of 10 µM. Compound vehicle was DMSO.

Article Snippet: M AN US CR IP T AC CE PT ED Graphical Abstract Compound 16 is associated with a 32-fold enhancement in the potency of clarithromycin against E. coli ATCC 25922 in vitro Graphical Abstract Compound 16 is associated with a 32-fold enhancement in the potency of clarithromycin against E. coli ATCC 25922 in vitro H2N H N NH2 16 H2N H N NH2 16 M AN US CR IP T AC CE PT ED -1- Structure-Activity Relationships of Potentiators of the Antibiotic Activity of Clarithromycin against Escherichia coli Gifty Blanksona, Ajit K. Parhia,c, Malvika Kaulb, Daniel S. Pilchb and Edmond J. LaVoiea aDepartment of Medicinal Chemistry, Rutgers, The State University of New Jersey, Piscataway, New Jersey, 08820, U.S.A. bDepartment of Pharmacology, Rutgers Robert Wood Johnson Medical School, Piscataway, New Jersey 08854, U.S.A cTAXIS Pharmaceuticals, Inc., Monmouth Junction, New Jersey 08552, U.S.A. 1.

Techniques: Inhibition, Concentration Assay

Journal:

Article Title: Geminal dialkyl derivatives of N -substituted pantothenamides: Synthesis and antibacterial activity

doi: 10.1016/j.bmc.2011.02.053

Figure Lengend Snippet: Structure of pantothenic acid and N-substituted pantothenamides

Article Snippet: A preliminary screen of these pantothenamides against other strains ( Acinetobacter baumannii ATCC 19606, Klebsiella penumoniae ATCC 13883, Escherichia coli ATCC 25922 and 11775, and Bacillus subtilis ATCC 6051 and 6633) using the agar diffusion method suggests no antimicrobial activity (inhibition zone <1.1 cm for a 1 cm disc impregnated with the desired compound). table ft1 table-wrap mode="anchored" t5 caption a7 MIC (μM) a S. aureus b MRSA c Open in a separate window 9a 7 ± 6 7± 3 Open in a separate window 9b 13 ± 7 13± 2 Open in a separate window 9c 101 ± 45 51 ± 15 Open in a separate window 9d 374 ± 187 374 ± 153 Open in a separate window 9e >715 >715 Open in a separate window 9f 3.2 ± 0.8 3.2 ± 0.9 Open in a separate window 9g >703 >703 Open in a separate window 9h >744 >744 Open in a separate window 9i 376 ± 217 376 ± 109 Open in a separate window 9j 1 ± 0.9 1 ± 0.7 Open in a separate window 9k(N5-pan) 7 ± 2 7 ± 2 Open in a separate window 9l (N9-pan) 0.4 ± 0.2 0.4 ± 0.2 Open in a separate window 9m 24 ± 14 24 ± 14 Open in a separate window a Minimum inhibitory concentrations (MICs) were determined using the following concentrations: 0.5, 1, 2, 4, 8, 16, 32, 64, 128, and 256 μg/mL.

Techniques:

Journal:

Article Title: Geminal dialkyl derivatives of N -substituted pantothenamides: Synthesis and antibacterial activity

doi: 10.1016/j.bmc.2011.02.053

Figure Lengend Snippet: Synthetic route to new N-substituted pantothenamides

Article Snippet: A preliminary screen of these pantothenamides against other strains ( Acinetobacter baumannii ATCC 19606, Klebsiella penumoniae ATCC 13883, Escherichia coli ATCC 25922 and 11775, and Bacillus subtilis ATCC 6051 and 6633) using the agar diffusion method suggests no antimicrobial activity (inhibition zone <1.1 cm for a 1 cm disc impregnated with the desired compound). table ft1 table-wrap mode="anchored" t5 caption a7 MIC (μM) a S. aureus b MRSA c Open in a separate window 9a 7 ± 6 7± 3 Open in a separate window 9b 13 ± 7 13± 2 Open in a separate window 9c 101 ± 45 51 ± 15 Open in a separate window 9d 374 ± 187 374 ± 153 Open in a separate window 9e >715 >715 Open in a separate window 9f 3.2 ± 0.8 3.2 ± 0.9 Open in a separate window 9g >703 >703 Open in a separate window 9h >744 >744 Open in a separate window 9i 376 ± 217 376 ± 109 Open in a separate window 9j 1 ± 0.9 1 ± 0.7 Open in a separate window 9k(N5-pan) 7 ± 2 7 ± 2 Open in a separate window 9l (N9-pan) 0.4 ± 0.2 0.4 ± 0.2 Open in a separate window 9m 24 ± 14 24 ± 14 Open in a separate window a Minimum inhibitory concentrations (MICs) were determined using the following concentrations: 0.5, 1, 2, 4, 8, 16, 32, 64, 128, and 256 μg/mL.

Techniques:

Journal:

Article Title: Geminal dialkyl derivatives of N -substituted pantothenamides: Synthesis and antibacterial activity

doi: 10.1016/j.bmc.2011.02.053

Figure Lengend Snippet: Antibacterial activity of N -substituted pantothenamides 9a–9m

Article Snippet: A preliminary screen of these pantothenamides against other strains ( Acinetobacter baumannii ATCC 19606, Klebsiella penumoniae ATCC 13883, Escherichia coli ATCC 25922 and 11775, and Bacillus subtilis ATCC 6051 and 6633) using the agar diffusion method suggests no antimicrobial activity (inhibition zone <1.1 cm for a 1 cm disc impregnated with the desired compound). table ft1 table-wrap mode="anchored" t5 caption a7 MIC (μM) a S. aureus b MRSA c Open in a separate window 9a 7 ± 6 7± 3 Open in a separate window 9b 13 ± 7 13± 2 Open in a separate window 9c 101 ± 45 51 ± 15 Open in a separate window 9d 374 ± 187 374 ± 153 Open in a separate window 9e >715 >715 Open in a separate window 9f 3.2 ± 0.8 3.2 ± 0.9 Open in a separate window 9g >703 >703 Open in a separate window 9h >744 >744 Open in a separate window 9i 376 ± 217 376 ± 109 Open in a separate window 9j 1 ± 0.9 1 ± 0.7 Open in a separate window 9k(N5-pan) 7 ± 2 7 ± 2 Open in a separate window 9l (N9-pan) 0.4 ± 0.2 0.4 ± 0.2 Open in a separate window 9m 24 ± 14 24 ± 14 Open in a separate window a Minimum inhibitory concentrations (MICs) were determined using the following concentrations: 0.5, 1, 2, 4, 8, 16, 32, 64, 128, and 256 μg/mL.

Techniques: Activity Assay

Journal: Molecules

Article Title: Pharmacological Activities and Characterization of Phenolic and Flavonoid Compounds in Methanolic Extract of Euphorbia cuneata Vahl Aerial Parts

doi: 10.3390/molecules26237345

Figure Lengend Snippet: Antimicrobial activity of different Euphorbia cuneata extracts against respiratory tract infection isolates measured as zone of inhibition diameter (ZOI, mm).

Article Snippet: Kirbag et al. [ ] also found that the antibacterial properties of methanolic extracts from particular Euphorbia species were the most effective against the tested microorganisms ( Staphylococcus aureus , Cowan 1; Bacillus megaterium , DSM 32; Proteus vulgaris , FMC 1; Klebsiella pneumonia , FMC 5; Escherichia coli , ATCC 25922; Pseudomonas aeruginosa , DSM 50071; Candida albicans , FMC 17; C. glabrata , ATCC 66032; C. tropicalis , ATCC 13803; Epidermophyton sp., and Trichophyton sp.).

Techniques: Activity Assay, Infection, Inhibition

Journal: Molecules

Article Title: Pharmacological Activities and Characterization of Phenolic and Flavonoid Compounds in Methanolic Extract of Euphorbia cuneata Vahl Aerial Parts

doi: 10.3390/molecules26237345

Figure Lengend Snippet: The values of MIC and MBC for the acetone, chloroform, and ethyl acetate extracts of Euphorbia cuneata against respiratory tract infection isolates.

Article Snippet: Kirbag et al. [ ] also found that the antibacterial properties of methanolic extracts from particular Euphorbia species were the most effective against the tested microorganisms ( Staphylococcus aureus , Cowan 1; Bacillus megaterium , DSM 32; Proteus vulgaris , FMC 1; Klebsiella pneumonia , FMC 5; Escherichia coli , ATCC 25922; Pseudomonas aeruginosa , DSM 50071; Candida albicans , FMC 17; C. glabrata , ATCC 66032; C. tropicalis , ATCC 13803; Epidermophyton sp., and Trichophyton sp.).

Techniques: Infection